Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,348 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed Not applicable Interventional Results available

Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)

NCT02746809
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
CoreValve Evolut 34R TAVR system
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

NCT03958409
View directory record Official record
Conditions
Skeletal Anomalies, Kidney Transplant; Complications
Interventions
measurements to evaluate metabolic bone disease, standard care
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 31, 2026, 2:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

NCT05002816
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Belantamab mafodotin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

NCT06580314
View directory record Official record
Conditions
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Biological · Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
676
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)

NCT04292899
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
4,891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
106
States / cities
Anaheim, California • Berkeley, California • Burlingame, California + 76 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 31, 2026, 2:30 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Setrusumab, Placebo
Biological · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
5 Years to 25 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Active, not recruiting Phase 2 Interventional

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial

NCT05247905
View directory record Official record
Conditions
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Interventions
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
171
States / cities
Fairbanks, Alaska • Phoenix, Arizona • Beverly Hills, California + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions
Vepugratinib, Placebo, EV, Pembrolizumab
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
64
States / cities
Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

NCT03309241
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

NCT06686797
View directory record Official record
Conditions
Healthy
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional

Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation

NCT01919346
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplantation, Complement Activity
Interventions
Eculizumab, Normal Saline
Drug
Lead sponsor
Heeger, Peter, M.D.
Individual
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
New Haven, Connecticut • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968
View directory record Official record
Conditions
Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Interventions
Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Paclitaxel, Ramucirumab
Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
536
States / cities
Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 357 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Active, not recruiting Not applicable Interventional Results available

Medtronic Transcatheter Aortic Valve Replacement (TAVR) Low Risk Bicuspid Study

NCT03635424
View directory record Official record
Conditions
Bicuspid Aortic Valve
Interventions
Medtronic TAVR Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Thousand Oaks, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT07269210
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Solbinsiran, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 3 Interventional

Homocysteine Study (HOST)

NCT00032435
View directory record Official record
Conditions
End Stage Renal Disease, Renal Failure
Interventions
PAL-40 Active, PAL-40 Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
36
States / cities
Birmingham, Alabama • Menlo Park, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors

NCT02650713
View directory record Official record
Conditions
Solid Tumors
Interventions
Atezolizumab, RO6958688
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Santa Monica, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

NCT05807490
View directory record Official record
Conditions
Healthy
Interventions
PF-07328948, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

NCT05822440
View directory record Official record
Conditions
Healthy
Interventions
PF-07817883, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 31, 2026, 2:30 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

NCT03526185
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 31, 2026, 2:30 AM EDT
Completed Not applicable Interventional

PRagmatic Trial Of Messaging to Providers About Treatment of Heart Failure in the Inpatient Setting

NCT04686604
View directory record Official record
Conditions
Heart Failure
Interventions
Best practice alert for the notification of patient HFrEF and recommended evidence-based medical therapies (NO drugs are being administered in this trial)
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 31, 2026, 2:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

NCT02349633
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
PF-06747775, Palbociclib, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Oct 31, 2026, 2:30 AM EDT
Completed No phase listed Observational

Driveline Silicone Skin Interface Registry

NCT01577433
View directory record Official record
Conditions
Driveline Heart-assisted Device Related Infection
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
15
States / cities
New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 31, 2026, 2:30 AM EDT